Have a feature idea you'd love to see implemented?
Let us know!
ITRM Iterum Therapeutics plc
Price (delayed)
$1.77
Market cap
$48.7M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2
Enterprise value
$57.7M
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people
Highlights
ITRM's EPS is up by 18% YoY
ITRM's quick ratio has dropped by 64% year-on-year but it is up by 11% since the previous quarter
The debt rose by 15% YoY and by 6% QoQ
The net income fell by 8% QoQ
Key stats
What are the main financial stats of ITRM
Market
Valuations
Earnings
Shares outstanding
27.52M
Market cap
$48.7M
Enterprise value
$57.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$28.14M
EBITDA
-$27.68M
Free cash flow
-$35.36M
Per share
Balance sheet
Liquidity
EPS
-$2
Free cash flow per share
-$1.76
Book value per share
-$0.51
Revenue per share
$0
TBVPS
$0.79
Total assets
$15.92M
Total liabilities
$27.43M
Debt
$22.44M
Equity
-$11.51M
Working capital
-$2.85M
Debt to equity
-1.95
Current ratio
0.85
Quick ratio
0.78
Net debt/EBITDA
-0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-160.8%
Return on equity
N/A
Return on invested capital
-187.8%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ITRM stock price
How has the Iterum Therapeutics stock price performed over time
Intraday
8.59%
1 week
30.15%
1 month
58.04%
1 year
3.51%
YTD
-10.15%
QTD
62.39%
Financial performance
How have Iterum Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.46M
Net income
-$30.55M
Gross margin
N/A
Net margin
N/A
The operating income has increased by 40% year-on-year and by 31% since the previous quarter
The net income fell by 8% QoQ
Growth
What is Iterum Therapeutics's growth rate over time
Valuation
What is Iterum Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ITRM's EPS is up by 18% YoY
Iterum Therapeutics's equity has decreased by 5% QoQ
Efficiency
How efficient is Iterum Therapeutics business performance
ITRM's ROA has shrunk by 179% YoY and by 42% QoQ
The ROIC has dropped by 64% since the previous quarter
Dividends
What is ITRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ITRM.
Financial health
How did Iterum Therapeutics financials performed over time
The total assets is 42% smaller than the total liabilities
ITRM's quick ratio has dropped by 64% year-on-year but it is up by 11% since the previous quarter
ITRM's current ratio has dropped by 64% year-on-year but it is up by 3.7% since the previous quarter
The debt to equity has plunged by 134% YoY
The debt rose by 15% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.